At a glance
- Originator Pfizer
- Class Anti-inflammatories; Phenols; Thiadiazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 12 May 1999 New profile
- 12 May 1999 Preclinical development for Inflammation in USA (PO)